Achilles Therapeutics Plc - ADR
ACHL
Get informed when a big investor buys or sells
+ FollowMarket Cap$60.83M
Close$
$3.18
114.5% upside
Current Fair Value
114.5% upsideUndervalued by 114.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $60.83 Million |
|---|---|
| Enterprise Value | $-21,604,000.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.74 |
| Beta | 1.25 |
| Outstanding Shares | 40,427,199 |
Return
| Return on Equity | -65.01% |
|---|---|
| Return on Assets | -54.66% |
| Return on Invested Capital | -69.30% |
Valuation & Multiples
| P/E Ratio | -0.85 |
|---|---|
| PEG | -4.87 |
| Price to Sales | - |
| Price to Book Ratio | 0.74 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.3 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.17 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
November 12, 2025
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.09%▲ 0.08% |
|---|---|
| Total Invested | $53,336▲ 581.87% |
| Investors Holding | 3▲ 1.00% |
ESG Score
No data
About Achilles Therapeutics Plc
Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has t...